

Press Release

Cellzome's CEO Tim Edwards new Chairman of UK's BioIndustry Association

Cambridge, United Kingdom, 2nd September 2010 - Cellzome is pleased to announce that Tim Edwards, the company's Chief Executive Officer, was elected new chairman of the board of the UK's biotech trade body, the BioIndustry Association (BIA).

Tim succeeds Dr Clive Dix, who steps down following two and a half years as BIA Chairman. Dr Dix will remain a member of the BIA Board.

Tim has nearly 20 years' experience in the healthcare industry, with over 10 years in senior executive positions in leading biotech companies. He has extensive business experience, particularly in the commercialization of science and technology with large pharmaceutical companies and is a keen advocate of the UK's biotechnology industry. Tim has been a member of the BIA board for nearly 3 years and is also Chairman of The Mulberry Bush Organisation and a Fellow of the RSA. From 2005-2007, he was Chairman of ReOx Limited, a biotech company spun out of the University of Oxford.

Dr Clive Dix, outgoing Chairman of the BIA, said:

"I am delighted that Tim has been elected as the new Chairman of the BIA. I am sure that his experience in the UK life sciences sector will be of great benefit to the organisation and its members."

Tim Edwards, CEO of Cellzome, said:

"I eagerly look forward to helping the BIA build on the successes it has achieved to date. The UK life sciences sector continues to face a number of challenges which the BIA can help its members address and overcome."

- ends -

For more information please contact:

Cellzome:

Tim Edwards
Chief Executive Officer
Tel: +49 (0) 6221-137 57-100
press@cellzome.com

Media contact:

Hogarth Partnership
Sarah MacLeod
Tel: +44 (0) 207 357 9477

About Cellzome

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment of inflammatory diseases.

Our pipeline of small-molecule therapeutics is driven by *Kinobeads*[™], a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called *Episphere*[™] to address epigenetic targets in disease-specific protein complexes. Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

Cellzome has two strategic alliances with GSK to discover and develop drugs to treat inflammatory diseases, the first in the field of kinase-targeted therapeutics and the second in the field of epigenetics.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two R&D laboratories in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: www.cellzome.com.

BioIndustry Association

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades.

With over 250 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society. For further information, please go to: www.bioindustry.org

The Mulberry Bush Organisation

The Mulberry Bush Organisation is a charity founded in 1948 providing therapeutic and residential care for children aged 5-12 with severe emotional and behavioural difficulties.

The RSA

The RSA is a charity founded in 1754 which drives ideas, innovation and social change.